Patents by Inventor Anthony B. Pinkerton

Anthony B. Pinkerton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10584103
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: March 10, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Patent number: 10577349
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 3, 2020
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ze'ev Ronai, Anthony B. Pinkerton, Yongmei Feng, Ivan Topisirovic, Kevin Brown, Christian A. Hassig
  • Patent number: 10570128
    Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 25, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Layton H. Smith
  • Publication number: 20200055875
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 20, 2020
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • Patent number: 10370333
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: August 6, 2019
    Assignee: SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Russell Dahl, Nicholas D. P. Cosford, Jose Luis Millan
  • Patent number: 10272074
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 30, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Christian A. Hassig, Michael R. Jackson, Robert John Ardecky, Ian Pass
  • Patent number: 10196369
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: February 5, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • Publication number: 20190023665
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Publication number: 20190010126
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Application
    Filed: February 5, 2018
    Publication date: January 10, 2019
    Inventors: Anthony B. PINKERTON, Russell DAHL, Nicholas D.P. COSFORD, Jose Luis MILLAN
  • Patent number: 10118902
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 6, 2018
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20180282289
    Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.
    Type: Application
    Filed: November 21, 2016
    Publication date: October 4, 2018
    Inventors: Takuya IKEDA, Yoshiyuki KOBAYASHI, Naoki MIYOSHI, Osamu SUZUKI, Takahiro NAGAYAMA, Takashi TSUJI, Layton H. SMITH, Anthony B. PINKERTON
  • Publication number: 20180207140
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
    Type: Application
    Filed: January 28, 2016
    Publication date: July 26, 2018
    Inventors: Anthony B. PINKERTON, Christian A. HASSIG, Michael R. JACKSON, Robert John ARDECKY, Ian PASS
  • Publication number: 20180118698
    Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
    Type: Application
    Filed: April 28, 2016
    Publication date: May 3, 2018
    Inventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
  • Publication number: 20180044324
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.
    Type: Application
    Filed: March 1, 2016
    Publication date: February 15, 2018
    Inventors: Ze'ev RONAI, Anthony B. PINKERTON, Yongmei FENG, Ivan TOPISIROVIC, Kevin BROWN, Christian A. HASSIG
  • Patent number: 9884826
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: February 6, 2018
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Russell Dahl, Nicholas D. P. Cosford, Jose Luis Millan
  • Publication number: 20170334889
    Abstract: N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 23, 2017
    Inventors: Jennifer E. Golden, Jeffrey Aube, Daniel P. Flaherty, Andrew M. Fribley, Randal J. Kaufman, Thomas D.Y. Chung, Anthony B. Pinkerton, Michael Pablo Hedrick
  • Patent number: 9776979
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 3, 2017
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • Publication number: 20170240514
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: June 24, 2015
    Publication date: August 24, 2017
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Patent number: 9732067
    Abstract: N-substituted sulfonylphenyl-5-mitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provided as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: August 15, 2017
    Assignees: University of Kansas, Sanford-Burnham Medical Research Institute, The Regents of the University of Michigan, Wayne State University
    Inventors: Jennifer E. Golden, Jeffrey Aube, Daniel P. Flaherty, Andrew M. Fribley, Randal J. Kaufman, Thomas D. Y. Chung, Anthony B. Pinkerton, Michael Pablo Hedrick
  • Publication number: 20170197958
    Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).
    Type: Application
    Filed: May 27, 2015
    Publication date: July 13, 2017
    Inventors: Anthony B. Pinkerton, Layton H. Smith